Thomas Weisel gives First Horizon outperform rating

First Horizon Pharmaceutical Corp. was given an outperform rating by Thomas Weisel Partners LLC analyst Donald B. Ellis. The analyst's view of prescription and sales data for the December quarter suggest that First Horizon is likely to report revenue of $65.4 million, in line with Thomas Weisel's revenue estimate of $65.3 million and ahead of the Street consensus revenue estimate of $64.2 million. Shares of the Alpharetta, Ga., pharmaceutical company were up $1.24, or 8.03%, at $16.80 on volume of 1,378,882 shares versus the three-month running average of 528,755 shares. (Nasdaq: FHRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.